Recent developments in the ability to predict and modify breast cancer risk

Journal of Plastic, Reconstructive and Aesthetic Surgery

Volumn 63, Issue 10, 2010, Pages 1581-1587

  Prado, Arturo ^a   Andrades, Patricio ^a   Parada, Francisco ^a  

^a HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

Author keywords

Breast cancer risk assessment; Prediction and modification of breast risk; Women at risk for breast cancer

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; EXEMESTANE; HORMONE RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

AGING; BACTERIAL GENE; BREAST BIOPSY; BREAST CANCER; BREAST RECONSTRUCTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SUSCEPTIBILITY; CATARACT; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; DENSITY; DISEASE ASSOCIATION; DISEASE MODEL; ENDOMETRIUM CANCER; FAMILIAL CANCER; FAMILY; FAMILY HISTORY; GENDER; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HIGH RISK POPULATION; HOT FLUSH; HUMAN; MASTECTOMY; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY; SURGICAL APPROACH; THROMBOEMBOLISM; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM; BIOPSY; BREAST NEOPLASMS; FEMALE; MAMMOGRAPHY; MASS SCREENING; MUTATION; OVARIECTOMY; PREDICTIVE VALUE; PROCEDURES; RADIOGRAPHY; RISK; RISK FACTOR; SALPINGOSTOMY; TUMOR SUPPRESSOR GENE;

BIOPSY; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MAMMOGRAPHY; MASS SCREENING; MASTECTOMY; MUTATION; OVARIECTOMY; PREDICTIVE VALUE OF TESTS; RISK; RISK ASSESSMENT; RISK FACTORS; SALPINGOSTOMY;

EID: 77956702366     PISSN: 17486815     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bjps.2009.06.034     Document Type: Review

References (43)

1. J.G. Elmore, K. Armstrong, and C.D. Lehman Screening for breast cancer JAMA 293 2005 1245 1256
2. H.K. Weir, M.J. Thun, and B.F. Hankey Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control J Natl Cancer Inst 95 2003 1276 1299
3. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement Ann Intern Med 143 2005 355 361
4. E.B. Claus, N. Risch, and W.D. Thompson Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction Cancer 73 1994 643 651
5. G.E. Palomaki, M.R. McClain, and K. Steinort Screen-positive rates and agreement among six family history screening protocols for breast/ovarian cancer in a population-based cohort of 21- to 55-year-old women Genet Med 8 2006 161 168
6. D.L. Wahner-Roedler, D.F. Nelson, and I.T. Croghan Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin lymphoma: Mayo Clinic experience Mayo Clin Proc 78 2003 708 715
7. G. Arpino, R. Laucirica, and R.M. Elledge Premalignant and in situ breast disease: biology and clinical implications Ann Intern Med 143 2005 446 457
8. H.J. Burstein, K. Polyak, and J.S. Wong Ductal carcinoma in situ of the breast N Engl J Med 350 2004 1430 1441
9. P.P. Rosen, C. Kosloff, and P.H. Lieberman Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years Am J Surg Pathol 2 1978 225 251
10. J.A. Urban Bilaterality of cancer of the breast. Biopsy of the opposite breast Cancer 20 1967 1867 1870
11. V.A. McCormack, and I. dos Santos Silva Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis Cancer Epidemiol Biomarkers Prev 15 2006 1159 1169
12. N.F. Boyd, H. Guo, and L.J. Martin Mammographic density and the risk and detection of breast cancer N Engl J Med 356 2007 227 236
13. J.P. Costantino, M.H. Gail, and D. Pee Validation studies for models projecting the risk of invasive and total breast cancer incidence J Natl Cancer Inst 91 1999 1541 1548
14. M.H. Gail, L.A. Brinton, and D.P. Byar Projecting individualized probabilities of developing breast cancer for white females who are being examined annually J Natl Cancer Inst 81 1989 1879 1886
15. B. Rockhill, D. Spiegelman, and C. Byrne Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention J Natl Cancer Inst 93 2001 358 366
16. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996 J Clin Oncol 1996 1730 1736 discussion 37-40
17. D.A. Berry, E.S. Iversen Jr., and D.F. Gudbjartsson BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes J Clin Oncol 20 2002 2701 2712
18. C. Boetes, J.O. Barentsz, and R.D. Mus MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique Radiology 193 1994 777 781
19. S.E. Harms, D.P. Flamig, and K.L. Hesley MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation Radiology 187 1993 493 501
20. S.H. Heywang-Kobrunner, U. Bick, and W.G. Bradley Jr. International investigation of breast MRI: results of a multicentre study (11 sites) concerning diagnostic parameters for contrast-enhanced MRI based on 519 histopathologically correlated lesions Eur Radiol 11 2001 531 546
21. C.D. Lehman Role of MRI in screening women at high risk for breast cancer J Magn Reson Imaging 24 2006 964 970
22. P.F. Liu, J.F. Debatin, and R.F. Caduff Improved diagnostic accuracy in dynamic contrast enhanced MRI of the breast by combined quantitative and qualitative analysis Br J Radiol 71 1998 501 509
23. D. Saslow, C. Boetes, and W. Burke American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography CA Cancer J Clin 57 2007 75 89 (Pubitemid 46535708)
24. A. McTiernan, C. Kooperberg, and E. White Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study JAMA 290 2003 1331 1336
25. A.H. Eliassen, G.A. Colditz, and B. Rosner Adult weight change and risk of postmenopausal breast cancer JAMA 296 2006 193 201 (Pubitemid 44050373)
26. L. Baglietto, D.R. English, and D.M. Gertig Does dietary folate intakemodify effect of alcohol consumption on breast cancer risk? Prospective cohort study BMJ 331 2005 807
27. S.A. Smith-Warner, D. Spiegelman, and S.S. Yaun Alcohol and breast cancer in women: a pooled analysis of cohort studies JAMA 279 1998 535 540 (Pubitemid 28113433)
28. A. Tjonneland, J. Christensen, and A. Olsen Folate intake, alcohol and risk of breast cancer among postmenopausal women in Denmark Eur J Clin Nutr 60 2006 280 286
29. R.L. Prentice, B. Caan, and R.T. Chlebowski Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial JAMA 295 2006 629 642 (Pubitemid 43209065)
30. C.F. Garland, F.C. Garland, and E.D. Gorham The role of vitamin D in cancer prevention Am J Public Health 96 2006 252 261
31. B. Fisher, J.P. Costantino, and D.L. Wickerham Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371 1388
32. E.R. Port, L.L. Montgomery, and A.S. Heerdt Patient reluctance toward tamoxifen use for breast cancer primary prevention Ann Surg Oncol 8 2001 580 585
33. V.G. Vogel, J.P. Costantino, and D.L. Wickerham Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 2006 2727 2741
34. M. Baum, A.U. Budzar, and J. Cuzick Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2002 2131 2139
35. J. Cuzick Aromatase inhibitors in prevention-data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study) Recent Results Cancer Res 163 2003 96 103 discussion 264-6
36. A.M. Geiger, O. Yu, and L.J. Herrinton A population-based study of bilateral prophylactic mastectomy efficacy in women at elevated risk for breast cancer in community practices Arch Intern Med 165 2005 516 520
37. L.C. Hartmann, D.J. Schaid, and J.E. Woods Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer N Engl J Med 340 1999 77 84
38. H. Meijers-Heijboer, B. van Geel, and W.L. van Putten Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation N Engl J Med 345 2001 159 164
39. T.R. Rebbeck, T. Friebel, and H.T. Lynch Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group J Clin Oncol 22 2004 1055 1062 (Pubitemid 41095038)
40. A.E. Giuliano, S. Boolbol, and A. Degnim Society of Surgical Oncology: position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007 Ann Surg Oncol 2007 2425 2427
41. S.M. Domchek, and T.R. Rebbeck Prophylactic oophorectomy in women at increased cancer risk Curr Opin Obstet Gynecol 19 2007 27 30
42. N.D. Kauff, J.M. Satagopan, and M.E. Robson Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation N Engl J Med 346 2002 1609 1615
43. T.R. Rebbeck, H.T. Lynch, and S.L. Neuhausen Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations N Engl J Med 346 2002 1616 1622